A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

NCT ID: NCT03106324

Last Updated: 2025-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

911 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-31

Study Completion Date

2026-01-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post authorization safety study is designed as prospective non interventional study for patients with newly diagnosed multiple myeloma who are not eligible for transplant. The objective is to compare the incidence of cardiovascular events between patients treated with a first-line lenalidomide containing regimen and those treated with a first-line non-lenalidomide containing regimen. Treatment in both cohorts will be done according to standard care. The study will gather risk factor information at baseline and throughout follow-up. Any cardiovascular event occurring will be assessed by an independent committee. Other safety endpoints will be collected through standard procedures. Observation period will be 3 years on treatment, with an additional evaluation of cardiovascular events 6 months' post treatment and a follow up period until 5 years after inclusion. During follow up the incidence of second primary malignancies (SPM) and overall survival will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TNE NDMM patients treated with lenalidomide regimen

Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide

Revlimid (lenalidomide)

Intervention Type DRUG

Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice

TNE NDMM patients treated with non-lenalidomide

Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide

Revlimid (lenalidomide)

Intervention Type DRUG

Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Revlimid (lenalidomide)

Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must have understood and voluntarily signed the Informed Consent Form (ICF)
2. Age ≥ 18 years at the time of signing the ICF
3. Newly diagnosed with multiple myeloma
4. Must not be eligible for transplant
5. Will be treated with a first-line lenalidomide-containing or nonlenalidomide-containing regimen, or currently is being treated with a first-line regimen and has received less than 2 cycles.

Exclusion Criteria

1. Prior treatment for Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma with lenalidomide, thalidomide, or pomalidomide or any agent considered to be a first-line Multiple myeloma (MM) therapy.
2. Prior treatment with lenalidomide, thalidomide, or pomalidomide or any agent considered to be a first-line MM therapy through clinical trial participation or patient access program
3. Two or more complete cycles of first-line therapy or any agent considered to be a firstline MM therapy for newly diagnosed multiple myeloma (NDMM) treatment before study enrollment
4. Refusal to participate in the Revlimid Transplant noneligible (TNE) Newly diagnosed multiple myeloma (NDMM) Post-authorization safety study (PASS) or current participation in the treatment phase of an interventional clinical trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Celgene

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb, MD

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Innsbruck University Hospital

Innsbruck, , Austria

Site Status

LKH Hochsteiermark

Leoben, , Austria

Site Status

University hospital St. Pölten

Pölten, , Austria

Site Status

CHU Saint-Pierre

Brussels, , Belgium

Site Status

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status

CHU-Charleroi

Brussels, , Belgium

Site Status

CHU-Charleroi

Charleroi, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

AZ Groeninge

Kortijk, , Belgium

Site Status

CHR Citadelle Liège

Liège, , Belgium

Site Status

Ziekehuis Oost Limburg

Limbourg, , Belgium

Site Status

CHU Ambroise Pare

Mons, , Belgium

Site Status

AZ Nikolaas

Sint Niklass, , Belgium

Site Status

CHPLT Verviers

Verviers, , Belgium

Site Status

CHU du Mont-Godinne

Yvoir, , Belgium

Site Status

Aalborg University Hospital

Aalborg, , Denmark

Site Status

Odense Hospital

Odense, , Denmark

Site Status

Hôpital privé d'Antony - Ramsay Générale de Santé

Antony, , France

Site Status

CH Victor Dupouy

Argenteuil, , France

Site Status

Polyclinique Bordeaux Nord Aquaitaine

Bordeaux, , France

Site Status

Hospital Prive Sevigne

Cesson-Sévigné, , France

Site Status

GHM Institut Daniel Hollard

Grenoble, , France

Site Status

Clinique Victor Hugo

Le Mans, , France

Site Status

CH de Libourne

Libourne, , France

Site Status

CH Mont de Marsan

Mont-de-Marsan, , France

Site Status

CHU de Nice

Nice, , France

Site Status

CHR Orleans

Orléans, , France

Site Status

CH St Jean

Perpignan, , France

Site Status

Centre Hospitalier Universitaire (CHU) de Saint-Etienne - Hopital Nord

Saint-Etienne, , France

Site Status

Hospital Prive de Villeneuve d'Ascq

Villeneuve-d'Ascq, , France

Site Status

W8 Praxis für Onkologie

Aachen, , Germany

Site Status

Klinikum St. Marien Amberg

Amberg, , Germany

Site Status

Sozialstiftung Bamberg

Bamberg, , Germany

Site Status

Charité - Universitätsmedizin Berlin - Campus Charité Mitte

Berlin, , Germany

Site Status

Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin

Berlin, , Germany

Site Status

Kliniken Berlin Köpenick

Berlin, , Germany

Site Status

HELIOS Klinikum Berlin Buch

Berlin, , Germany

Site Status

Gemeinschaftpraxis Pott/Tirier/Hannig

Bottrop, , Germany

Site Status

Onkologie Koln

Cologne, , Germany

Site Status

Medizinische Klinik II, DONAUISAR Klinikum Deggendorf, Akademisches Lehrkrankenhaus der Medizinischen Hochschule Hannover

Deggendorf, , Germany

Site Status

St. Bernward Krankenhaus GmbH

Hildesheim, , Germany

Site Status

Stadt. Krankenhaus Kiel, 2.med Klinik,

Kiel, , Germany

Site Status

Dres. Neise & Lollert, Praxis für Hämatologie & Onkologie

Krefeld, , Germany

Site Status

MVZ Mitte - Onkologische Schwerpunktpraxis

Leipzig, , Germany

Site Status

Lübecker Onkologische Schwerpunktpraxis

Lübeck, , Germany

Site Status

Klinikum Magdeburg

Magdeburg, , Germany

Site Status

Internistische Facharztzentrum mit Dialyse

Memmingen, , Germany

Site Status

Stauferklinikum

Mutlangen, , Germany

Site Status

Onko-Log Mulheim Gbr

Mülheim, , Germany

Site Status

Medizinisches Zentrum für Hämatologie und Onkologie München MVZ GmbH

München, , Germany

Site Status

Klinikum Nord, Klinik für Innere Medizin 5

Nuremberg, , Germany

Site Status

Onkologische Praxis Oldenburg

Oldenburg, , Germany

Site Status

Kreiskliniken Reutlingen

Reutlingen, , Germany

Site Status

Das Diak

Schwäbisch Hall, , Germany

Site Status

Klinikum Sindelfingen, Med.Klinik I

Sindelfingen, , Germany

Site Status

Onkologicum Stuttgart

Stuttgart, , Germany

Site Status

Ueboroertliche Berugsausuebungsgemeinschaft

Troisdorf, , Germany

Site Status

Kliniken Villingen-Schwenningen

Villingen-Schwenningen, , Germany

Site Status

Lahn-Dill-Kliniken

Wetzlar, , Germany

Site Status

Hämatologie / Internistische Onkologie

Wiesbaden, , Germany

Site Status

Midlands Regional Hospital , Hematology/Oncology

Country Offaly, , Ireland

Site Status

Waterford Regional Hospital, Waterford

Waterford, , Ireland

Site Status

Ospedale di Ivrea

Chivasso, Corso Galileo Ferraris, 3 Chivasso, Italy

Site Status

Ospedale Alessandria, Via Venezia, 16, 15121 Alessandria AL

Allessandria, , Italy

Site Status

Centro di Riferimento Oncologico di Aviano

Avianno, , Italy

Site Status

UO di Ematologia Osp. Mons Di Miccolis

Barletta, , Italy

Site Status

Istituto di Ematologia ed Ocnologia Medica "Seràgnoli" AUO Sant'Orsola - Bologna

Bologna, , Italy

Site Status

UO di Ematologia Osp. Perrino

Brindisi, , Italy

Site Status

Ospedale di Circolo di Busto Arsizio

Busto Arsizio, , Italy

Site Status

"S.C. di Ematologia e Centro Trapianti di Cellule Staminali Emopoietiche

Cagliari, , Italy

Site Status

Dipartimento di Oncologia Medica e Chirurgica AORN S. Anna e S. Sebastiano

Caserta, , Italy

Site Status

AO Garibaldi Catania - Via Palermo 636

Catania, , Italy

Site Status

AO Garibaldi Catania

Catania, , Italy

Site Status

Ospedale Ivrea , Areas Medica

Ivrea, , Italy

Site Status

Ospedale dell'Angelo

Mestre, , Italy

Site Status

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

Milan, , Italy

Site Status

ASST Grande Ospedale Metropolitano Niguarda

Milan, , Italy

Site Status

Opsedale di Bolzano

Milan, , Italy

Site Status

ASST Grande Ospedale Metropolitano Niguarda - Piazza Ospedale Maggiore, 3 -

Milan, , Italy

Site Status

Ospedale Maggiore di Novara

Novara, , Italy

Site Status

UO Ematologia e Centro Trapianti di Midollo Osseo dell'Ospedale San Francesco di Nuoro

Nuoro, , Italy

Site Status

IRCCS Policlinico di Pavia

Pavia, , Italy

Site Status

UO di Ematologia Osp. S. Carlo - Potenza

Potenza, , Italy

Site Status

Servizio immunoematologia e medicina trasfusionale-ASP

Ragusa, , Italy

Site Status

S.C. Ematologia, Dip.to Oncologico e Tecnologie Avanzate

Reggio Emilia, , Italy

Site Status

A.O Bianchi Melacrino Morelli - Presidio Riuniti

Regio Calabria, , Italy

Site Status

Ospedale Sant'Eugenio

Rome, , Italy

Site Status

Policlinico Gemelli Roma

Rome, , Italy

Site Status

UOSD Ematologia Complesso Opsedaliero-Ospedale S. Spirito e Nuovo Regina Margherita

Rome, , Italy

Site Status

Ospedale di Circolo, Fondazione Macchi

Varese, , Italy

Site Status

Ospdeale Policlinico Borgo Roma

Verona, , Italy

Site Status

Ospedale Belcolle Viterbo

Viterbo, , Italy

Site Status

Rode Kruis Hospital

Beverwijk, , Netherlands

Site Status

Nij Smellinghe

Drachten, , Netherlands

Site Status

Catharina Hospital, Hemato-Oncology

Eindhoven, , Netherlands

Site Status

Admiraal de Ruyter Hospital

Goes, , Netherlands

Site Status

Röpcke-Zweers Hospital

Hardenberg, , Netherlands

Site Status

Academic Hospital Maastricht

Maastricht, , Netherlands

Site Status

University Medical Center Utrecht

Utrecht, , Netherlands

Site Status

VieCuri Medical Center

Venlo, , Netherlands

Site Status

Helse Førde HF sentralsjukehuset

Førde, , Norway

Site Status

Akershus universitetssykehus HF

Lørenskog, , Norway

Site Status

Hospital de Jerez

Cadiz, , Spain

Site Status

Hospital Santa Lucía

Cartagena, , Spain

Site Status

Hospital de Jaen

Jaén, , Spain

Site Status

IP HULA

Lugo, , Spain

Site Status

Hospital Universitario Quironsalud Madrid

Madrid, , Spain

Site Status

Hospital Universitario Central Asturias

Oviedo, , Spain

Site Status

Son Espases

Palma de Mallorca, , Spain

Site Status

Complejo Universitario Navarra

Pamplona, , Spain

Site Status

Hospital Manises

Valencia, , Spain

Site Status

Skåne University Hospital, Lund

Lund, , Sweden

Site Status

Northern Health and Social Care Trust -Antrim Area Hospital

Antrim, , United Kingdom

Site Status

South Eastern Health and Social Care Trust - The Ulster Hospital

Belfast, , United Kingdom

Site Status

Birmingham Heartlands Hospital

Birmingham, , United Kingdom

Site Status

Betsi Cadwaladr University Health Board - Glan Clwyd Hospital

Bodelwyddan, , United Kingdom

Site Status

Southmead Hospital -North Bristol NHS Trust

Bristol, , United Kingdom

Site Status

Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust

Cosham, , United Kingdom

Site Status

Lincoln County Hospital

Lincoln, , United Kingdom

Site Status

The Clatterbridge Cancer Centre NHS Foundation Trust - The Royal Liverpool Hospital

Liverpool, , United Kingdom

Site Status

St Georges Hospital

London, , United Kingdom

Site Status

Norfolk and Norwich University Hospital

Norfolk, , United Kingdom

Site Status

Southend Hospital

Southend-on-Sea, , United Kingdom

Site Status

Royal Stoke Hospital

Stoke-on-Trent, , United Kingdom

Site Status

Worcestershire Acute Hospitals NHS Trust - Worcestershire Royal Hospital

Worcester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Denmark France Germany Ireland Italy Netherlands Norway Spain Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1194-5810

Identifier Type: OTHER

Identifier Source: secondary_id

CC-5013-MM-034

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.